Get the Stockscreener App
4.68
2.09%
-0.11
Coya Therapeutics Inc stock is traded at $4.68, with a volume of 53,184.
It is down -2.09% in the last 24 hours and up +3.30% over the past month.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
See More
Previous Close:
$4.79
Open:
$4.81
24h Volume:
53,184
Relative Volume:
0.27
Market Cap:
$109.78M
Revenue:
$7.94M
Net Income/Loss:
$-21.13M
P/E Ratio:
-4.3261
EPS:
-1.0818
Net Cash Flow:
$-16.17M
1W Performance:
+1.08%
1M Performance:
+3.30%
6M Performance:
+0.86%
1Y Performance:
-23.74%
1-Day Range:
$4.63
$4.81
1-Week Range:
$4.52
$4.85
52-Week Range:
$3.7101
$7.75
Coya Therapeutics Inc Stock (COYA) Company Profile
Name
Coya Therapeutics Inc
Sector
Industry
Phone
650.739.3939
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Compare COYA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
4.68 | 112.36M | 7.94M | -21.13M | -16.17M | -1.0818 |
VRTX
Vertex Pharmaceuticals Inc
|
515.23 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.36 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
991.43 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.76 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.49 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-09-25 | Initiated | Lake Street | Buy |
| Dec-04-24 | Initiated | D. Boral Capital | Buy |
Coya Therapeutics Inc Stock (COYA) Latest News
COYA|Coya Therapeutics Inc|Price:4.790|Chg%:+0.120 - TradingKey
Chardan Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics Inc (COYA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Form 8K Coya Therapeutics Inc For: 11 August By Investing.com - Investing.com Nigeria
Coya Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Coya Therapeutics posts investor presentation on Treg-directed combination therapy for neurodegenerative diseases - Bitget
Coya Therapeutics reports Q2 2026 net loss $6.64M, cash $43.2M; ALSTARS Phase 2 enrollment on track - TradingView
Coya Therapeutics Q2 net loss widens as R&D costs rise - TradingView
Coya Therapeutics Reports Q2 Net Loss of $6.6 Million - Quiver Quantitative
Coya Therapeutics (NASDAQ: COYA) details Q2 2026 results, ALS Fast Track and cash runway - Stock Titan
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - Business Wire
Coya Therapeutics (NASDAQ:COYA): What Could Today’s Update Reveal About Clinical Execution And Funding Priorities? - kalkinemedia.com
Coya Therapeutics (COYA) Earnings Date and Reports 2026 - MarketBeat
IMDX Stock Price and Chart — NASDAQ:IMDX - tradingview.com
Coya Therapeutics (NASDAQ: COYA) names Mark Pavao to its Audit Committee - Stock Titan
Coya Therapeutics, Inc. Appoints Mark H. Pavao to Its Audit Committee of Board, Effective August 7, 2026 - marketscreener.com
Coya Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Treg Therapy Market - Future Market Insights
Coya Therapeutics (COYA) Expected to Release Earnings on Tuesday - MarketBeat
Avoiding Lag: Real-Time Signals in (COYA) Movement - Stock Traders Daily
Coya Therapeutics (COYA) Holds Steady at $4.0 Amid Key Support and Resistance BattleMomentum Surge Alerts - dars.gov.et
Coya Therapeutics (NASDAQ: COYA) holder discloses 3.3% stake in amended filing - Stock Titan
Coya Therapeutics Inc (COYA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Coya Therapeutics Inc (COYA) Balance Sheet - TradingKey
Coya Therapeutics Inc (COYA) Cash Flow - TradingKey
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Coya Therapeutics Inc (COYA) Valuation: PE, PB & Fair Value Analysis - TradingKey
COYA|Coya Therapeutics Inc|Price:4.250|Chg%:-0.130 - TradingKey
Coya Therapeutics Inc (COYA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Coya Therapeutics Inc (COYA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Coya Therapeutics Market Sentiment - Benzinga España
Coya Therapeutics Inc (COYA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Coya Therapeutics Inc (COYA) Income Statement - TradingKey
Coya Therapeutics, Inc. Revenue Breakdown – NASDAQ:COYA - TradingView
Coya Therapeutics (NASDAQ:COYA) Trading Up 0.2%Should You Buy? - MarketBeat
Discipline and Rules-Based Execution in COYA Response - Stock Traders Daily
Price to book forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Price to earnings forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Price to sales forward of Coya Therapeutics, Inc. – NASDAQ:COYA - TradingView
Coya Therapeutics (COYA) Dips 1.3% as Stock Tests Key Support LevelsBear Pennant - dars.gov.et
Houston ALS Biotech Coya Eyes 2028 Approval Path - Streetwise Reports
Coya Targets ALS Trial Readout in Q1 2027, H.C. Wainwright Sets US$18 Price Target - Streetwise Reports
Coya Therapeutics (COYA) Holds Steady at $5.26 as Trading Range NarrowsIV Crush Alert - dars.gov.et
Coya Therapeutics(COYA) Stock Options Chain | Quotes & News - Moomoo
Coya Therapeutics (COYA) Slips 1.87% as Stock Tests Key Support Near $5.00Triple Top - dars.gov.et
Coya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative Disease - AOL.com
Analysts Are Bullish on Top Healthcare Stocks: Coya Therapeutics, Inc. (COYA), Palisade Bio (PALI) - The Globe and Mail
COYA Q1 2026 Earnings: Narrower-Than-Expected Loss as Pipeline AdvancesProfitability Analysis - dars.gov.et
Roth MKM Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Coya Therapeutics Inc Stock (COYA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.00%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):